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Abstract
Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich
lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease. Accumulating evidence
indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism,
but also participates in the atherosclerotic lesion formation and several other pathological processes involved
in atherosclerosis. Based on data from experiments and clinical trials, some novel therapies such as antisense
technology emerge.
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Background
Triglyceride (TG) has been identified as an important
risk factor for cardiovascular disease (CVD) for a long
time, but randomized controlled trials of fenofibrate and
omega-3 fatty acids to reduce TG failed to show any
significant clinical benefits [1, 2]. Although genome-wide
association study (GWAS) has positioned some single
nucleotide polymorphisms (SNPs) associated with TG to
be linked with CVD, these SNPs have pleiotropic rela-
tionships with other lipids [3] and therefore TG-related
effects may be confounded. The longstanding contro-
versy renders TG not to be a persuasive biomarker in
CVD pathogenesis. Renewed interest in TG is brought by
recent genetic observations that loss-of-function (LOF)
mutations in the gene encoding apolipoprotein C-III
(apoCIII) and relevant hypotriglyceremia are associated
with decreased CVD risk (40–41 %) [4, 5]. ApoCIII, an
apolipoprotein composed of 79 amino acids with a
molecular weight of 8.8 kDa, resides on circulating
HDL, low density lipoprotein (LDL) and triglyceride-
rich lipoproteins (TRLs) such as chylomicrons (CM)
and very low density lipoprotein (VLDL) [6]. ApoCIII
promotes hypertriglyceridemia (HTG) via different
mechanisms. First, apoCIII inhibits the activity of lipo-
protein lipase (LPL) and disturbs lipids lipolysis [6].
Second, apoCIII interferes with the binding of
apolipoprotein B (apoB) or apolipoprotein E (apoE) to
hepatic receptors, thus leading to a delayed catabolism
of TRL remnants [6]. Third, apoCIII favors the assem-
bly and secretion of VLDL in the liver [7, 8]. ApoCIII
and the lipoproteins that carry apoCIII acts as not only
a key regulator in the TG metabolism, but also an inde-
pendent predictor for CVD risk [9, 10]. The negative ef-
fects of apoCIII agree with gene analysis in which null
mutation or missense mutation of apoCIII produces
apoCIII deficiency and confers lifelong cardioprotection
[4, 5, 11, 12]. These evidence supports the hypothesis that
apoCIII may be instrumental to mediate TG-related harm-
ful effects. This review puts emphases on the newly-
discovered function of apoCIII beyond the well-known
regulator of triglyceride metabolism. The novel method
to inhibit apoCIII via antisense oligonucleotide (ASO)
treatment and selective capture of apoCIII via zeolite
nanoparticles will be mentioned too.
ApoCIII is directly involved in atherogenesis
Evidence from basic experiments
ApoCIII facilitates interaction of monocytes and
endothelial cells
Interaction between monocytes and endothelial cells
(ECs) is the initial step in the formation of atherosclerotic
lesion [13]. ApoCIII itself and apoB lipoproteins containing
apoCIII could activate pertussis toxin (PTX)-sensitive G
protein pathway to activate phosphatidylcholine-specific
phospholipase (PC-PLC). PC-PLC can catalyze PC to
* Correspondence: pengdaoquan@yeah.net
Department of Cardiovascular Medicine, The Second Xiangya Hospital,
Central South University, Changsha, Hunan 410011, China
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Luo and Peng Lipids in Health and Disease  (2016) 15:184 
DOI 10.1186/s12944-016-0352-y
phospholylcholine and diacylglycerol (DAG) , and then
DAG induces protein kinase C (PKC) α activation and
leads to activation of nuclear factor-κB (NF-κB) [14],
which increases β1-integrin expression in monocytes
and enhances their adhesion to ECs. Besides, apoCIII
also activates PKC β, leading to NF-κB activation and
vascular cell adhesion molecule-1 (VCAM-1) expres-
sion in ECs, which contributes to EC dysfunction and
monocyte recruitment [15] (Fig. 1). All of these findings
can be demonstrated not only under static conditions
but also under laminar flow. Since apoCIII can directly
affect the interaction between monocytes and ECs,
more attention is given to the direct atherogenic effects
of apoCIII. A recent study by Zheng et al. extends the
experiments from venous endothelium to coronary ar-
tery endothelium and provides in vivo evidence for the
independent atherogenic effects of apoCIII and athero-
protective effects of statins because of decreasing apoCIII
[16]. The study has demonstrated that apoCIII can pro-
mote NF-κB and subsequent VCAM-1 expression, leading
to EC activation and monocytes adhesion, all of which can
be abolished by statin effectively [16]. Although these
findings seem to have built a complete line of evidence
to explain the effects of apoCIII on vascular inflamma-
tion, many questions, for example, how apoCIII acti-
vates PTX-sensitive G protein , how apoCIII activates
PKC β, are there any other mediators used by apoCIII
to activate PKC α beyond PTX senstive G protein, are
there any other molecules can also be affected by sta-
tins to reduce vascular inflammation, still require further
exploration.
ApoCIII promotes smooth muscle cell proliferation
Smooth muscle cells (SMCs) have been identified as an
crucial participant in the progression of atherosclerotic
lesion and neointimal formation. A recently published
article demonstrates that apoCIII can promote SMC
proliferation via Akt signalling pathway mediated by
reactive oxygen species in vitro, leading to aggravated
restenosis and atherogenesis [17] (Fig. 1). The re-
searchers built reliable HTG models through human
apoCIII transgenic (apoCIIItg) mice and observed signifi-
cant atherosclerotic lesion development in apoCIIItg
mice with LDL receptor deficient background. Fur-
thermore, they crossed apoCIIItg or apoCIII−/−mice
with glycosylphosphatidylinositol-anchored high density
lipoprotein-binding protein 1-deficient (GPIHBP1−/−)
mice, which exhibited extreme HTG because of im-
paired LPL anchoring to ECs, and harvested authentic
TRL with or without apoCIII (TRL+ apoCIII or TRL–
apoCIII) from the crossed mice to further distinguish
the effect between TRL and apoCIII without impairing
TRL properties. It was shown that TRL+ apoCIII pro-
moted SMC proliferation while TRL–apoCIII not. The
study adds more weight to the hypothesis that apoCIII
























Fig. 1 Pleiotropic effects of apoCIII. PKC indicates protein kinase C; NF-κB, nuclear factor-κB; VCAM-1, vascular cell adhesion molecule-1; EC, endothelial
cells; ROS, reactive oxygen species; SMC, smooth muscle cells; HDL, high density lipoprotein; SR-BI, scavenger receptor class B type I
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significant difference exists between apoCIII−/−and
WT mice, which seems contradicted with findings from
human researches that apoCIII LOF mutation provides
cardioprotection [4, 5]. This may be caused by species
difference that deletion of mouse apoCIII is not the
same as apoCIII LOF mutation in human. Overall,
more experiments are still needed to address the role of
human apoCIII on human atherogenesis and restenosis.
Evidence from clinical studies
ApoCIII alters platelet activity
Platelets and the coagulation system are importantly in-
volved with atherogenesis and atherothrombosis [18].
Results from a prospective study concerning 663 sub-
jects with angiographically proven CVD suggest that
basal serum concentration of apoCIII ≥ 10.5 mg/dl rep-
resents an independent risk factor of overall and cardio-
vascular mortality in a 5-year follow-up [19] (Table 1).
Besides, the sub-analysis from this study reveals an inde-
pendent association between elevated apoCIII and en-
hanced thrombin generation [19]. Moreover, another
retrospective study about 933 unrelated patients enrolled
in Verona heart Study has found that increased concen-
tration of apoCIII is associated with elevated thrombin
level in the plasma even after adjustment for other risk
factors and apoCIII presents similar correlation with the
presence of Factor II (FII) G20210A gene variant, the
most important genetic determinant of FII and heredi-
tary risk factor for venous thrombosis [20] (Table 1). It’s
noteworthy that no significant relationship has been
observed between thrombin activity and TRLs [20].
Although no causal mechanism could be inferred from
these analysis because of the intrinsically flaw of cross-
sectional design, they indicate that apoCIII could alter
the homeostatic balance in a procoagulant way and may
promote atherothrombotic complications.
ApoCIII modifies risk factors of atherosclerosis
Evidence from clinical studies
HDL dysfunction
HDL has been reported to exert various atheroprotec-
tive properties, including anti-apoptotic effects, anti-
inflammatory effects and cholesterol efflux capacity
[21]. All of these can be altered by pathological disorders
and HDL with defects in these properties is referred to as
dysfunctional HDL, which in turn contributes to the dis-
orders, especially CVD.
Accumulating evidence suggests that apoCIII corre-
lates tightly with HDL dysfunction. A prospective case-
control study has identified two types of HDL: HDL with
apoCIII and HDL without apoCIII, and the two HDL
subgroups are oppositely related to CVD risk. The ad-
justed relative risk per standard deviation for HDL-C
with apoCIII is 1.18 (1.03–1.34) and for HDL-C without
apoCIII is 0.66 (0.53–0.83) [22] (Table 1). In a compara-
tive study, apolipoprotein A-I containing HDL particles
with apoCIII is significantly higher in obese subjects
than normal weight (10 % vs. 4 %, P = 0.009) and apoCIII
concentration in these HDL particles is 1.5–2 times
higher in obese subjects (P ≤ 0.004), both of which indi-
cated increased risk for CVD [23] (Table 1). In the Chin-
Shan Community Cardiovascular Cohort study in Taiwan,
HDL apoCIII to VLDL apoCIII ratio is considered as a
more reliable marker to predict CVD than conventional
apolipoproteins or lipid factors (odds ratio: 2.04; 95 % CI:
1.46–2.84; P < 0.0001) [24] (Table 1).
Besides, the concentration of apoCIII in HDL is sig-
nificantly higher in CVD patients than in non-CVD
patients according to the results from enzyme-linked
immunosorbent assay method [25] (Table 1) and mass
spectrometry [26]. ApoCIII increase in HDL from CVD
patients can activate mitogen-activated protein kinase
(MAPK) signalling pathway via phosphorylation of p38
in ECs and thus increase the expression of pro-apoptotic
protein tBID, altering HDL from anti-apoptotic to pro-
apoptotic [26] (Fig. 1).
The HDL dysfunction related to apoCIII is not only
seen in CVD patients, but also seen in patients with
chronic kidney disease (CKD). Holzer et al. found that
apoCIII was highly abundant in HDL isolated from
hemodialysis patients and correlated inversely with HDL
cholesterol efflux capacity [27]. However, the study did
not analyze the relationship between apoCIII and other
changed HDL components which may also affect HDL
cholesterol efflux capacity in CKD. Therefore, it’s unreli-
able to justify that enrichment of HDL with apoCIII
would impair HDL cholesterol efflux capacity independent
of other HDL components.
These findings indicate that apoCIII increases in HDL
may exert some disruptive impacts on HDL functional
properties and provide a novel mechanism for HDL
dysfunction.
Evidence from basic experiments
Diabetes mellitus
Patients with diabetes mellitus often display abnormal
lipid profiles and are susceptible to CVD. Elevated glucose
can upregulate apoCIII expression in the transcriptional
level via the activation of transcription factors carbohy-
drate response element-binding protein and hepatocyte
nuclear factor-4α and thus plasma apoCIII concentration
presents a positive correlation with fasting plasma glucose
as well as glucose excursion after oral glucose load in
obese humans [28]. However, the relationship between
insulin and apoCIII still remains controversial.
In vitro experiments have shown that apoCIII interacted
with scavenger-receptor BI (SR-BI) and then upregulated
β1 integrin expression, leading to the hyperactivation of β
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Table 1 Summary of studies investigating the relationship between apoCIII and cardiovascular risk
Study Study design Study population (n) Mean age (y) Male (%) apoCIII levels (mg/dl) Lipid levels (mg/dl) Key study findings







60.2 81.5 % 11.3a NR 154.9 220.8 46.3 147.9 Serum apoCIII≥ 10.5 mg/dl
represents an independent
risk factor of overall
(HR, 2.22; 95 % CI,
1.16–4.24; P = 0.016) and
cardiovascular mortality
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HDL with apoCIII (OR, 1.18;
95 % CI, 1.03–1.34; P = 0.01)
and HDL without apoCIII
(OR, 0.66; 95 % CI,
0.53–0.83; P = 0.0001)







(n = 20) vs normal
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(n = 20)
51 vs 51 35 % vs 35 % 13.2 vs 7.5 11.9 vs 6.7 153 vs 83 210 vs 187 50 vs 65 130 vs 105 ApoCIII containing HDL
particles (11.4 vs 5.2) and
apoCIII concentration in
HDL particles (11.9 vs 6.7)
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independent predictor of
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1.00–1.08; P = 0.039).
ApoCIII indicates apolipoprotein CIII, HDL high density lipoprotein, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein-cholesterol, CVD cardiovascular disease, NHS Nurses’ Health Study, HPFS Health


















cell Ca2+ channels through the coactivation of PKA and
Src kinase pathways [29] (Fig. 1). This finding has been
supported by another study carried on a special animal
model diabetes-prone BB rat, which develops type 1 dia-
betes mellitus (T1DM) at around the age of 60 days spon-
taneously [30]. Of note, antisense treatment to decrease
the level of endogenous apoCIII can delay the onset of
T1DM [30], which suggests that apoCIII is an essential
participant in the development of T1DM.
As for T2DM, it’s well-known that it is featured by
two major defects: insulin resistance and β cell failure. A
cross-sectional study about 1422 T2DM subjects found
that apoCIII correlated positively with coronary artery
calcification, a biomarker of subclinical atherosclerosis
[31]. Juntti-Berggren et al. found that islet insulin resist-
ance could promote local apoCIII production [32]. Be-
sides, they transplanted apoCIII knockout islet and islet
from ob/ob or B6 mice into the anterior chamber of the
eye in an ob/ob mouse or a HFD-treated B6 mice, both
of which were characterized by high systemic serum
levels of apoCIII and impaired glucose tolerance [32]. By
this way a delicate system was created where the islets
rich and deficient in apoCIII coexisted in one animal
model . The elevation of intraislet apoCIII production
increased local inflammation, deranged Ca2+ handling in
β cells and thus β cell apoptosis [32]. From this perspec-
tive, ApoCIII serves as a bridge linking insulin resistance
and β cell failure in T2DM. Besides, systemically de-
creasing apoCIII in vivo via ASO treatment can improve
glucose tolerance in T2DM [32].
In contrast to the studies above, one study investigated
effects of apoCIII on intact rat pancreatic islets in the
presence of proinflammatory cytokines ( interferon-γ +
interleukin 1β) to find that apoCIII reduced β cell apop-
tosis by stimulating phosphorylation of Akt [33]. The
disagreement may be caused by the differences about ex-
periment factors such as models and intervention
methods. Of note, it’s inappropriate to draw a conclusion
from one study that apoCIII may exert some protective
function on islet cells.
Lp-PLA2
Although whether lipoprotein-associated phospholipase
A2(Lp-PLA2) is an independent risk factor for athero-
sclerosis remains controversial, Lp-PLA2 activity and
mass shows a strong, positive association with athero-
sclerosis [34]. Results from in vitro experiments and
animal models revealed that apoCIII could upregulate
Lp-PLA2 expression via MAPK and NF-kB pathways in
a dose- and time-dependent manner and thus induce
inflammation [35]. In addition, in vitro experiments
indicated that the downstream Lp-PLA2 could also in-
crease apoCIII expression in the liver in turn [35].
However, the detailed mechanisms in the circle still
await further investigation.
Future prospects
Species-specific antisense suppression of apoCIII has pro-
duced robust reduction in serum apoCIII and TG and
demonstrated good tolerance in various preclinical models,
including human apoCIII transgenic mice, rats, mouse,
nonhuman primates [36]. In the phase I clinical study
in healthy human volunteers, administration of human
apoCIII ASO (volanesorsen, formally ISIS-APOCIIIRx)
brought about a profound dose- and time-dependent
reduction of apoCIII and TG without remarkable adverse
effects [36]. The phase 2 study evaluated the pharmacody-
namic effects of volanesorsen in adult patients with severe
or uncontrolled HTG [37]. When volanesorsen was ad-
ministrated as a single agent, plasma apoCIII was reduced
on apoB100 and apoAI containing lipoproteins as well as
lipoprotein (a) uniformly [38] in a dose-dependent fashion
(apoCIII: 40 %-100 mg, 63.8 %-200 mg, 79.6 %-300 mg).
TG decreased in concordance with apoCIII (TG: 31.3 %-
100 mg, 57.7 %-200 mg, 70.9 %-300 mg) and showed a
strong, positive correlation with apoCIII, while HDL-C
presented a dose-dependent increase (HDL-C: 36.6 %-
100 mg, 36.2 %-200 mg, 45.7 %-300 mg). Similar changes
occurred when volanesorsen was given as an add-on to
stable fibrate therapy. No serious treatment-associated
safety issues were identified. The apparent clinical benefits
brought by volanesorsen presented not only in patients
with HTG but also in those with familial chylomicronemia
syndrome (FCS). In FCS patients, absence of LPL caused
insufficient TRLs removal and resulted in chylomicrone-
mia (TG > 880 mg/dl). ASO treatment exhibited substan-
tial efficacy to lower TG less than 500 mg/dl independent
of LPL [39]. Short-term efficacy and apparent safety of
volanesorsen brings light to further long-term evaluation.
Ongoing phase III trials about volanesorsen include the
APPROACH (the APPROACH study: A Study of ISIS-
APOCIIIRx in Patients with Famial Chylomicronemia
Syndrome, NCT02211209), the COMPASS (the COM-
PASS study: A Study of Volanesorsen in Patietns with
Hypertriglyceridemia, NCT02300233), and the BROADEN
(the BROADEN study: A Study of Volanesorsen in Patients
with Partial Lipodystrophy, NCT02527343). These studies
aim to evaluate the efficacy and safety of 300 mg vola-
nesorsen versus placebo administered subcutaneously
once a week for 52 ,26, 52 weeks respectively in pa-
tients with corresponding diseases. The primary out-
come is measured by the percent change in fasting TG
from baseline to 13 weeks. ApoCIII ASO treatment
links genetic insights to molecular mechanisms and
keeps abreast with the ‘precision medicine’.
In addition to the promising ASO treatment, zeolite
nanoparticles, whose negative charge help it to interact
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electrostatically with the positively charged amino acid
residues of apoCIII , selectively capture plasma apoCIII
and may be a potential therapy to reduce plasma apoCIII
in the future [40].
Conclusions
Considerable evidence indicates that apoCIII can affect the
development of CVD not only by regulating triglyceride
metabolism but also through its direct atherogenic effects.
Novel understanding of apoCIII in atherogenesis makes it
an attractive therapy target and some innovative approaches
to modifying it emerge. Although full illustration of apoCIII
function still awaits further exploration, to lower the apoC-
III levels in circulation via specific intervention seems to be
an intriguing therapy for cardiovascular protection.
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